NKTR  valuation analysis

Name: Nektar Therapeutics
Description: Nektar Therapeutics, a biopharmaceutical company, researches and develops drug candidates for cancer and auto-immune disease in the United States. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: Nov 05, 2020
Market cap: $4.20B (698th)
Sales(TTM): $163.31M (1239th)
Earnings(TTM): -$440.68M (1167th)

FFER: 5.23*
Actual price: $23.44
* Earnings were reported Feb 25, 2021 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2021-03-03
Price & Estimates
Sales & Earnings history (TTM)
No notables found through heuristics.
Earnings / MarketCap
Nektar Therapeutics
"Biotechnology" industry
Sales / MarketCap
Nektar Therapeutics
"Biotechnology" industry
Book / MarketCap
Nektar Therapeutics
"Biotechnology" industry
Equity / Assets
Nektar Therapeutics
"Biotechnology" industry